NCT05330182

LMN-201 for Prevention of C. Difficile Infection Recurrence

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2024-08-29Est. Completion: 2027-06-01

Enrollment target: 375 participants

Locations

Kaiser Permanente, Escondido, California, United States
Bridgeport Hospital, Bridgeport, Connecticut, United States
Gastroenterology Center of Connecticut, Hamden, Connecticut, United States
GI PROS Research, Naples, Florida, United States
Metro Infectious Disease Consultants - Atlanta, Decatur, Georgia, United States
Snake River Research, Idaho Falls, Idaho, United States
Metro Infectious Disease Consultants, LLC, Burr Ridge, Illinois, United States
DM Clinical Research, Oak Lawn, Illinois, United States
Baptist Health Research, Lexington, Kentucky, United States
University of Minnesota, Minneapolis, Minnesota, United States
Mercury Street Medical, Butte, Montana, United States
Quality Clinical Research, Inc, Omaha, Nebraska, United States
Weill Cornell Medicine, New York, New York, United States
IMA Clinical Research, Mount Airy, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC, Annandale, Virginia, United States

Other microbiome trials you might be interested in

Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationPhase 2Recruiting

Acute Leukemia in RemissionMyelodysplastic SyndromesMyeloproliferative SyndromeHodgkin LymphomaLymphoma, Non-HodgkinMyelomaChronic Lymphocytic Leukemia

The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic h…

Amiens, FranceEst. completion May 2030

View Trial →

AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisRecruiting

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.